

# GENENTECH

## Request for an ICD-10-PCS Code for Administration of Tecentriq (atezolizumab)

---

Centers for Medicare & Medicaid Services  
ICD-10 Coordination and Maintenance Committee Meeting  
March 17, 2020

# Tecentriq (atezolizumab) Is a PD-L1 Blocking Antibody and the First Cancer Immunotherapy Approved in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer

An immunotherapy that renders cancer cells susceptible to attack by the patient's immune system<sup>1</sup>

The first FDA-approved treatment option in ES-SCLC in more than 20 years<sup>2</sup>

An NCCN-preferred (category 1) option for patients with ES-SCLC<sup>3</sup>

Under consideration by CMS for the NTAP for FY2021

NCCN – National Comprehensive Cancer Network; ES-SCLC – Extensive Stage Small Cell Lung Cancer; PD-L1 – Programmed Death-Ligand 1; NTAP – New Technology Add-On Payment


1. Tecentriq (atezolizumab) [prescribing information]. San Francisco, CA: Genentech, Inc.; 2019.

2. [F. Hoffman-La Roche Ltd. FDA approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer.](#) Accessed January 20, 2020.

3. [National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Small Cell Lung Cancer Version 1.2020.](#) Accessed January 20, 2020.

# Small Cell Lung Cancer Is Generally a Disease of Older People and Is a Significant Burden to the Medicare Population

## Percent of New Lung Cancer Cases by Age Group<sup>1</sup>



**SCLC** is the most aggressive of all lung cancers and accounts for about

**10–15%**  
of lung cancer cases<sup>2</sup>

**About 72%**

of SCLC cases are diagnosed at the extensive stage,<sup>3</sup> which is associated with a **5-year survival rate of only 2.9%**<sup>4</sup>

1. [National Cancer Institute. Cancer of the Lung and Bronchus – Cancer Stat Facts. Surveillance, Epidemiology, and End Results \(SEER\) Program.](#) Accessed January 20, 2020.


2. [WebMD, LLC. Types of Lung Cancer.](#) Accessed January 20, 2020.

3. [American Lung Association. Trends in Lung Cancer Morbidity and Mortality.](#) Accessed January 20, 2020.

4. [Noone AM, Howlander N, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2015, based on November 2017 SEER data submission, posted to the SEER website, April 2018. Bethesda, MD: National Cancer Institute. 2018.](#) Accessed January 20, 2020.

# Tecentriq Was Studied in a Global Phase 1 / Phase 3, Double-blind, Randomized, Placebo-controlled Trial in Patients with ES-SCLC<sup>1</sup>

## IMpower133



RECIST – Response evaluation criteria in solid tumors; ECOG – Eastern Cooperative Oncology Group; PS – Performance Status; AUC – Area Under the Curve

1. Horn L, Mansfield AS, Szczesna A, et al. First-Line Atezolizumab plus Chemotherapy in ES-Small-Cell Lung Cancer. *N. Engl. J. Med.* 2018;379(23):2220-2229. doi:10.1056/nejmoa1809064.

# Tecentriq Was Found to Have Benefitted Patients, Including Improved Overall Survival<sup>1,2</sup>

1. Overall survival was significantly longer in the Tecentriq plus standard-of-care arm (median, 12.3 months) than in the placebo plus standard-of-care arm (median, 10.3 months).<sup>\*</sup> The stratified hazard ratio for death was 0.70 (95% CI, 0.54 to 0.91).
2. Progression-free survival was significantly longer in the Tecentriq plus standard-of-care arm (median, 5.2 months) than in the placebo plus standard-of-care arm (median, 4.3 months)<sup>\*\*</sup>
3. Tecentriq was associated with numerically improved health-related quality-of-life and reduced symptoms, compared to patients in the placebo plus standard-of-care arm

CI – Confidence interval; HR – Hazard ratio

<sup>\*</sup>Median, 12.3 months; 95% CI, 10.8 to 15.9) vs median, 10.3 months; 95% CI, 9.3 to 11.3

<sup>\*\*</sup>Median, 5.2 months; 95% CI, 4.4 to 5.6 vs median, 4.3 months; 95% CI, 4.2 to 4.5

1. Horn L, Mansfield AS, Szczesna A, et al. First-Line Atezolizumab plus Chemotherapy in ES-Small-Cell Lung Cancer. *N. Engl. J. Med.* 2018;379(23):2220-2229. doi:10.1056/nejmoa1809064.

2. Tecentriq (atezolizumab) [Primary CSR Study GO30081]. San Francisco, CA: Genentech, Inc.; 2018.

# Due to the Severity of ES-SCLC, Treatment Must Commence as Soon as Possible After Diagnosis

Many ES-SCLC patients are diagnosed in the inpatient setting with the initial treatment being administered inpatient as well

Subsequent doses of Tecentriq are administered in the outpatient setting

# The ICD-10-PCS 'X' Code Has Been Established As The Most Appropriate Way For Hospitals To Achieve Payment For NTAP-approved Therapies

Tecentriq is being considered by CMS for the NTAP for FY2021 for the treatment of ES-SCLC

Current ICD-10-PCS codes do not adequately describe the administration of Tecentriq for the ES-SCLC indication

The ICD-10-PCS 'X' code has been established as the most appropriate way for hospitals to achieve payment for NTAP-approved therapies

Therefore, please create a new ICD-10-PCS 'X' code for Tecentriq for the ES-SCLC indication